Open AccessDurable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma
Author(s) -
Maria Estela MartínezEscala,
Timothy M. Kuzel,
Jason Kaplan,
Adam M. Petrich,
Beatrice Nardone,
Steven T. Rosen,
Joan Guitart
Publication year - 2016
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2016.0004
Subject(s) - romidepsin , medicine , mycosis fungoides , regimen , adverse effect , lymphoma , surgery , histone deacetylase , biochemistry , chemistry , gene , histone
Romidepsin is a histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma (CTCL). Durable responses have been published without establishing a standard recommendation about duration of treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom